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cannot be assessed by usual efﬁcacy and safety clinical endpoints.
Hence, the aim of the current evaluation was to compare the
perceived convenience of the once-weekly injection regimen of
Idraparinux (IDRA), with no need for monitoring, to usual VKA
treatment. METHODS: A total of 2556 patients with Atrial
Fibrillation, enrolled in an international randomized open-label
Phase III trial comparing IDRA to VKA, completed a self-
administered questionnaire assessing treatment convenience and
their satisfaction with it. The Perception AntiCoagulant Treat-
ment Questionnaire (PACT-Q) previously validated, measured
expectations (7 items) at baseline, treatment Convenience (13
items) and Satisfaction (7 items) both at 3 and 6 months (M3,
M6). Convenience and Satisfaction scores ranged from 0 (worst)
to 100 (best). Primarily IDRA was compared to VKA Conve-
nience scores at M3. Treatment comparisons (ANOVA) were
also performed on Satisfaction score, at M6 and with covariates
adjustment. RESULTS: Baseline expectations were comparable
between treatment groups. Mean Convenience scores at M3
were signiﬁcantly higher in IDRA than VKA (90.3 vs. 85.6,
p < 0.001). This result was maintained when adjusted for
country, age, gender, prior medication, and baseline expectations.
The better convenience of IDRA over VKA was conﬁrmed at M6.
Similar ﬁndings were shown on Satisfaction scores. CONCLU-
SION: Idraparinux was perceived as more convenient and satis-
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OBJECTIVE: Evaluate the opinions of Canadian physicians
and patients towards adherence with cholesterol treatment.
METHODS: A convenience sample of 362 general practitioners
recruited across Canada completed a physician questionnaire. A
minimum of 20 statin patients per physician completed question-
naires during normally scheduled visits. An independent third
party collected and analyzed the data. Each physician received
aggregate practice level and entire patient cohort data.
RESULTS: A total of 13,508 patients participated; 42% of
cohort was 65 years or older. Reported medical conditions: 55%
high BP, 59% high LDL, 27% heart problems, 29% diabetes,
18% obesity, 6% stroke. Patient reasons for stopping statins:
26% don’t like taking medication, 20% needed more informa-
tion on side effects, 14% improved their diet or lost weight, 10%
needed more information on beneﬁts of statins. Physician opin-
ions on why patients have poor compliance to statins: 80%
resistance to taking medications, 68% side effects of medication,
64% lack understanding of the beneﬁts of statin therapy, 25%
achieved weight loss or diet improvements. Patient reported
factors that would motivate them to stay on therapy: 36% seeing
a printout of my levels, 32% knowing more about risks of high
cholesterol, 31% having the doctor discuss cholesterol in more
detail, 25% knowing more about my medication. Physician opin-
ions on key patient compliance motivators: 83% discussing cho-
lesterol issues with patients, 79% follow up discussion on levels,
72% discussing medications, 61% diet and lifestyle support
program. Medication change preference if not reaching LDL
target–patient vs. physician: Increase dose 51% vs. 75%, change
statin 40% vs. 7%, add another drug 9% vs. 19%. CONCLU-
SION: Differences exist in physician and patient reported reasons
for adherence to statin therapy. Understanding these differences
may assist physicians to counsel their patients more effectively
and possibly improve adherence.
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OBJECTIVE: To construct risk models linking psychological risk
factors with the risk of myocardial infarction (MI) and stroke.
METHODS: The Caerphilly Prospective Study (CaPS) comprises
a general population sample of 2959 men aged 45–59, followed
up for 20 years. Psychological Distress Indicator (PDI) was
constructed based on GHQ30; anxiety was measured with State
Trait Anxiety Questionnaire; type A behaviour with Jenkins
Activity Survey and Health Attitude Inventory; and anger with
four Framingham anger scales. Logistic, fractional polynomial
and Cox’s proportional hazards models were used to analyse the
data. A multivariate analysis that included standard and psycho-
logical risk factors was carried out. Composite indices based on
the sum of the main effects for the individual psychological risk
factors and main effects with interactions were developed.
RESULTS: In univariate analyses, no signiﬁcance was found for
psychological distress, anxiety, type A behaviour and anger mea-
sured on three scales for both MI and stroke. In men with low
anger-out scores, the odds ratio and hazard ratio of MI were
OR = 1.75 [95% CI: 1.25–2.43] and HR = 1.75 [95% CI: 1.28–
2.40], respectively, relative to men with high anger-out scores.
Cardiovascular risk explained by psychological factors increased
by up to 21.5% when adjusted for the regression dilution bias.
When adjusted for standard risk factors, the hazard ratio of MI
in men with high anger-out score was 1.64 (p = 0.007). When
psychological risk factors were combined, the risks were
HR = 2.26 [1.26, 4.06] and HR = 2.72 [1.23, 6.01] for alterna-
tive indices. The risk of stroke was not associated with any
psychological risk factors. CONCLUSION: Individual psycho-
logical risk factors were found to be of limited signiﬁcance in
cardiovascular risk prediction. Composite indices of psychologi-
cal outcomes were signiﬁcantly associated with the increased risk
of MI; such measures of psychological risk could be considered in
risk equations.
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OBJECTIVE: Major risk factors for Stroke are well known and
are relatively easy to assess in community screens. However, less
than one-third of all persons found to have modiﬁable risk
factors follow–up with a primary care physician up to six months
post screening. This study tested the effectiveness of a patient
counselor intervention to enhance motivation and reduce barri-
ers in seeking medical advice regarding screen-detected sroke
risk. METHODS: A total of 227 patients identiﬁed as having risk
of Stroke were randomly allocated either to an experimental
group that received a telephonic intervention (patient counselor)
or a telephonic intervention plus physician notiﬁcation of study
results or were assigned to a control group that received usual
care (advice only) and were followed for six months. Follow-up
data was collected at three months post screening visit.
RESULTS: MD visits after screening date had increased signiﬁ-
cantly in intervention group compared to control group from
baseline levels (70.1% versus 52.9%, p-value < 0.05). We further
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stratiﬁed our analysis among patients with 2 or more risk factors,
and found that 72% returned to see the physician within the
intervention group compared to 59 % of the control group
(p-value < 0.05). The intervention also produced a signiﬁcant
increase in the percentage of patients who reported they were
conﬁdent about lowering stroke risk with the physician assis-
tance (69% versus 52%, p-value < 0.05). After confounder
adjustment, patients in the intervention group were still 1.8 times
more likely to visit their physicians than patients in the control
group, in multivariate analyses (p < 0.05). CONCLUSION: This
randomized controlled trial illustrates that provision of tele-
phonic intervention is effective in increasing patient visits to the
physician after stroke screening. These results can be used to
maximize the clinical utility of risk factor identiﬁcation in high
risk communities.
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OBJECTIVE: The 14-item Treatment Satisfaction Questionnaire
for Medication Version I (TSQM) is a reliable and valid instru-
ment to assess patients’ satisfaction with medication, providing
scores on four scales—side effects, effectiveness, convenience and
global satisfaction. In naturalistic studies, using the TSQM with
the side effects domain has a potential to interfere with routine
medical care. In this study, an interactive voice response system
(IVRS)-administered abbreviated 9-item TSQM without the ﬁve
items of the side effects domain (TSQM-9) was psychometrically
evaluated among patients taking antihypertensive medication.
METHODS: A total of 396 subjects who self-reported taking a
prescribed antihypertensive medication were recruited from an
online panel. The subjects were asked to complete the TSQM-9
at the start of the study, along with the modiﬁed Morisky scale,
and then again within 7 to 14 days. Psychometric analyses
including conﬁrmatory factor analysis (CFA), Cronbach’s
alpha and intraclass correlation coefﬁcients were conducted.
RESULTS: There was evidence of construct validity of the
TSQM-9 based on the CFA ﬁndings of the observed data
ﬁtting the Decision Balance Model of Treatment Satisfac-
tion even without the side effects domain (Non-normed Fit
Index = 0.9791; Bentler’s Comparative Fit Index = 0.9860).
TSQM-9 domains had good internal consistency as evident from
Cronbach’s alpha values of 0.84 and greater. TSQM-9 domains
also demonstrated good test-retest reliability with high intraclass
correlation coefﬁcients exceeding 0.70. As expected, the
TSQM-9 domains were able to differentiate between individuals
who were high compliers with medication use and those that
were low compliers, with a moderate-to-high effect size (Cohen’s
d ranging from 0.6 to 0.8). There was evidence of convergent
validity with signiﬁcant correlations with the medication adher-
ence scale. CONCLUSION: The IVRS-administered TSQM-9
was found to be a reliable and valid measure to assess treatment
satisfaction in naturalistic study designs, in which there is poten-
tial for the TSQM’s side effects domain to interfere with routine
clinical care.
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OBJECTIVE: To measure the impact of patient targeted educa-
tion designed to inform atorvastatin users of lower cost anti-
hyperlipidemic alternatives after atorvastatin was removed
from their formulary. METHODS: A retrospective case-control
research design was used with case and control groups composed
of clients that implemented the formulary change on January 1,
2006 and had ﬂat 3-tier copayments. Case group members were
enrolled in clients that implemented a targeted communication
strategy and control group members did not. Success was mea-
sured as switching to a formulary antihyperlipidemic on or after
June 30, 2006. Logistic regression models, estimated separately
for retail and home delivery (HD) channels, was used to estimate
the impact of education on the likelihood of switching control-
ling for age, gender, high dose (40 or 80 MG), prior switching,
household median income, non-preferred and generic copayment
differential, and other client-level trend programs (i.e., step
therapy). RESULTS: A total of 201,223 patients in the control
group and 165,758 patients in the case group met the study
inclusion criteria. Controlling for patient and plan covariates,
patients in the case group in retail were 3.48 times more likely
to switch to a preferred statin (95% Conﬁdence Interval
(CI) = 3.38–3.59) compared to control group members. In HD,
the likelihood of switching was 9.82 (95% CI = 9.46–10.20).
This translates into an absolute increase in the switch rates of
14.3 and 29.8 percentage points for patients in retail and HD,
respectively. CONCLUSION: In the context of a formulary
change, targeted member communication and assistance is an
effective means of promoting lower cost formulary alternatives.
Greater conversion in HD may be related to a higher degree of
assistance and outreach within this channel.
CARDIOVASCULAR DISORDERS—Health Care Use &
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OBJECTIVE: To assess the clinical effectiveness and cost-
effectiveness of low-density-lipoprotein (LDL) apheresis for
treatment of patients with homozygous (HMZ) and heterozy-
gous (HTZ) familial hypercholesterolemia (FH). METHODS:
Seven case series and one retrospective review with heparin-
induced extracorporeal LDL precipitation (HELP) for the treat-
ment of refractory HMZ and HTZ FH published between
January 1998 and May 2007 were included in the analysis.
RESULTS: The mean acute decrease in LDL-C ranged from
53–77% with HELP. The mean chronic decrease in LDL-C
ranged from 9–46% and the increase in HDL-C ranged from
12–27%. The LDL:HDL ratio exceeded target values. There was
a beneﬁcial impact on coronary outcomes demonstrated by a
decrease in Agatston scores and a regression in atherosclerotic
lesions. Adverse events, ranging 2.9–5.1%, were typically mild
and related to vascular access problems. Studies were generally of
low quality however performing controlled studies is not feasible
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